Philip Tagari switches Amgen’s discovery lab for insitro’s machine learning tools; CEO Joaquin Duato to chair J&J’s board

Philip Tagari

In February, Philip Tagari will take a few days of retirement and then immediately return to industry. He won’t be leading the therapeutics discovery unit for a large biopharma, though.

He’ll trade in his Amgen hat for chief scientist at a machine learning…